BTK Inhibitors Explained: How Targeted Therapy Is Changing Blood Cancer
BTK inhibitors are a form of targeted therapy for blood cancer. By selectively attacking a protein that B cell cancers need to survive and grow, these medications give doctors a way to treat the disease with precision.1 BTK inhibitors have become an important treatment for B cell cancers; the FDA has approved indications across multiple products to treat diagnoses that include:2
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- Mantle cell lymphoma (MCL)
- Waldenström’s macroglobulinemia (WM)
- Marginal zone lymphoma (MZL)
- Follicular lymphoma (FL)
Below, we’ll explain how BTK inhibitors work, how they fit into the evolution of B cell cancer treatment, and what sets them apart. We’ll also discuss their role in precision medicine with a focus on CLL and how doctors may personalize care. Finally, we’ll explore how BeOne Medicines is advancing targeted therapies and the future of BTK inhibitors.
How do BTK inhibitors work?
In CLL/SLL, MCL, and other B cell cancers; a type of white blood cell called B cells become abnormal.3 These cancer cells depend on a signal to survive and make more of themselves.
The BTK protein (known to researchers as Bruton’s tyrosine kinase) belongs to a series of proteins that generate this signal.1
BTK inhibitors work by binding to the BTK protein. With the inhibitor attached, the protein can’t do its job. And, without BTK, the cell can’t generate the signal it needs to survive and multiply — disrupting the cancer.1
BTK inhibitors disrupt a signal cancer cells need to survive.
From chemotherapy to targeted therapy
BTK inhibitors became available a little more than 10 years ago. Since the mid-20th century, doctors have used chemotherapy as the primary approach for treating blood cancer.4 Chemotherapy drugs work by killing rapidly dividing cells, regardless of whether they are in a tumor or part of healthy tissue.5 In the 2000s, doctors began combining chemotherapy with immunotherapy (chemoimmunotherapy). Immunotherapy which works by helping the body’s immune system fight cancer.6
Meanwhile, targeted cancer therapeutics had been gaining momentum.7 Chemotherapy drugs work by interfering with proteins that the cancer needs.8 In 2013, the FDA approved the first BTK inhibitor.9 Research has shown the benefit of this precision approach. A long-term clinical trial following people who took this initial BTK inhibitor found it delays the progression of CLL and extends lives.10
Further clinical research has made more options available today. The FDA has approved other BTK inhibitors, including second-generation versions designed to improve their effectiveness and safety.11
Why does selectivity matter?
All BTK inhibitors block the BTK protein by attaching to it, but they don’t all work in exactly the same way. One of the most important differences is in their selectivity — that is how precisely a particular inhibitor finds and disrupts the BTK protein, and nothing else.12
Some BTK inhibitors are more precise than others. The less selective an inhibitor is, the more likely that it could interfere with other proteins that healthy cells need.13 This imprecise targeting can lead to side effects that are not directly related to cancer. Depending on the nature of these effects, a doctor may discuss other treatment options.13 Over time, researchers have designed BTK inhibitors to be more selective for BTK.13
What is precision medicine in blood cancer?
Precision medicine focuses on providing the right treatment based on genetic or molecular understanding of the disease.14 It’s a significant change from the traditional one-size-fits-all model, in which treatments were chosen with little consideration for the differences among individuals or each person’s unique cancer.15
This could matter in blood cancer because two people with the same diagnosis, such as CLL, may respond differently to the same treatment. That’s because CLL, like other blood cancers, is not a one-size-fits-all disease. Its behavior is shaped by many factors, including the cancer’s genetic makeup, someone’s overall health, and even the medications they are currently on or have previously taken.16,17
Targeted therapies, such as BTK inhibitors, and immunotherapies are both forms of precision medicine. To determine what approach may work best for someone, doctors can look for certain markers, called biomarkers, in blood or tissue samples.18,19
What does precision medicine look like in CLL?
People whose cancer cells have a mutation in a gene called TP53 tend not to respond well to chemotherapy, so doctors may recommend targeted therapies instead.20 Separately, the mutational status of the IGHV gene also helps doctors tailor therapy. People with mutated IGHV may experience a more long-lasting benefit with chemotherapy compared to those with unmutated IGHV. Meanwhile, targeted therapies like BTK inhibitors show benefit for both mutated and unmutated IGHV.21
As a consequence, two CLL patients may have significantly different treatment plans, based solely on the molecular nature of their disease.20,21
What is personalized care?
While the biology of someone’s disease is very important, it’s not the only factor that a doctor will weigh when considering how best to treat someone. Other important factors include:22,23
- Other health conditions someone has, such as heart disease or high blood pressure
- Other medications the person is taking
- The person’s age and overall fitness
- Whether the goal is to control disease over the long term or to achieve a deep,potentially treatment-free remission
- The person’s own preferences and priorities
How is BeOne advancing research for targeted therapies?
As a global oncology company and the maker of a second-generation BTK inhibitor, BeOne has spent more than a decade working to advance targeted therapy for blood cancers — with the goal of making them more effective, longer lasting, and easier to tolerate.
In May and June 2026, BeOne researchers presented findings from more than 60 studies at two of the most prominent international gatherings in oncology: the annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). The research spans blood cancers and solid tumors, and ranges from early-stage clinical findings to long-term outcome data. Some studies examine biomarkers that may help predict how individual patients respond to treatment; others look at how treatment effects translate into the lived experiences of patients.
Together, these studies reflect BeOne’s commitment to developing medicines that tackle the most pressing needs of those diagnosed with cancer — today and into the future.
The future of BTK Inhibitors
Today’s BTK inhibitors represent meaningful progress for B cell cancer treatment. But researchers continue to push forward.
As more patients are treated with these medications, they want to know what happens in the years to follow. A clinical trial following people with CLL/SLL taking a BTK inhibitor has found that the medication continues to control the disease, even after six and a half years.24 Those 80 years old and older experience the same benefit.24 Meanwhile, some studies are pairing BTK inhibitors with other medications, and other research is testing a different approach to blocking BTK by destroying it altogether.24
Researchers are also looking for insights to make BTK inhibitor therapy more precise. These include studying how best to tailor treatment for mutations such as TP53, del(17p)25 and IGHV26 and examining when to stop or restart therapy.
The research underway today suggests approaches to B cell cancer treatment will continue to evolve. So, it’s important to stay up to date. Finding the right approach may require an ongoing conversation with your doctor.27